Ichihara Asako, Jinnin Masatoshi, Ihn Hironobu
Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):208-210. Epub 2017 Apr 19.
Systemic sclerosis (SSc) is a chronic autoimmune disease characterised by fibrosis, inflammation and vasculopathy in the skin and internal organs. Recently, several articles described that Th17 cells, IL-23 and IL-17 levels were significantly elevated in the peripheral blood or fibrotic sites of SSc. We report a case of SSc and psoriasis administered ustekinumab, IL-12/IL-23 inhibitor. In this case, the skin tightening was successfully improved and ustekinumab was more effective, even though oral prednisolone (9-12 mg/day) had some effect on skin tightening and arthralgia. We consider that inhibition of Th17 cytokines may lead to therapeutic efficacy against SSc. Ustekinumab has the potential for a treatment option of SSc.
系统性硬化症（SSc）是一种慢性自身免疫性疾病，其特征为皮肤和内脏器官出现纤维化、炎症和血管病变。最近，几篇文章描述了在SSc患者的外周血或纤维化部位，Th17细胞、IL-23和IL-17水平显著升高。我们报告了1例同时患有SSc和银屑病的患者使用乌司奴单抗（一种IL-12/IL-23抑制剂）进行治疗的病例。在该病例中，皮肤紧绷症状得到了成功改善，且乌司奴单抗的效果更佳，尽管口服泼尼松龙（9 - 12毫克/天）对皮肤紧绷和关节疼痛也有一定效果。我们认为抑制Th17细胞因子可能会产生针对SSc的治疗效果。乌司奴单抗有潜力成为SSc的一种治疗选择。
